GlassScriptPhysician profile
Rajiv Perinbasekar
NPI 1801281738
$4,462.32
in general payments reported to CMS, 2019-2025
30 companies · $701 in 2025
The $701 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $463 · 2022: $1,647 · 2023: $1,003 · 2024: $648 · 2025: $701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,352.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $989.99 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $653.69 | 2021-2025 | Xifaxan, Plenvu, Trulance |
| Celgene Corporation | $491.22 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $340.50 | 2022-2025 | Entyvio |
| Ardelyx, INC. | $241.31 | 2022-2025 | Ibsrela |
| Gilead Sciences, INC. | $221.19 | 2022-2025 | |
| Madrigal Pharmaceuticals | $148.00 | 2025 | Rezdiffra |
| Ferring Pharmaceuticals INC. | $147.59 | 2022-2024 | Rebyota |
| Genzyme Corporation | $121.99 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $121.41 | 2021-2023 | Dificid |
| Janssen Biotech, INC. | $120.93 | 2024-2025 | Tremfya, Stelara, Simponi |
| Phathom Pharmaceuticals, INC. | $100.21 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $99.27 | 2021-2023 | |
| Braintree Laboratories, INC. | $97.05 | 2022-2023 | Sutab, Suflave |
| Novo Nordisk INC | $96.14 | 2023-2025 | Wegovy |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $82.34 | 2021-2024 | Linzess |
| Alfasigma USA, INC. | $80.05 | 2021-2022 | |
| Lilly USA, LLC | $50.76 | 2024-2025 | Omvoh, Zepbound |
| Qol Medical, LLC | $46.16 | 2025 | Sucraid |
| Amgen INC. | $35.68 | 2023 | Amjevita, Avsola |
| Pfizer INC. | $31.73 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.14 | 2023-2024 | Cyltezo |
| Intercept Pharmaceuticals, INC. | $22.01 | 2024 | |
| Capsovision, INC. | $21.24 | 2024 | Capsocam Plus |
| Lucid Diagnostics INC. | $19.47 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $18.23 | 2025 | Dupixent |
| Currax Pharmaceuticals LLC | $15.61 | 2025 | Contrave |
| Astrazeneca Pharmaceuticals LP | $15.11 | 2021 | |
| Micro-Tech Endoscopy USA, INC. | $2.30 | 2023 | Blueboost |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajiv Perinbasekar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.